In our Supplemental Newborn Screening Program in western Pennsylvania, we have introduced not only a unique approach to newborn screening, but also some innovative concepts in follow-up confirmation and prognostic diagnosis. The Pennsylvania Department of Health routinely screens only for phenylketonuria and congenital hypothyroidism. In an attempt to extend this basic state-mandated screening program, we developed, in 1986, the concept of an independent supplemental fee-for-service screening program. At present we are screening 37 hospitals plus a number of nurse midwifery programs in western Pennsylvania and eastern Ohio. We routinely screen for 11 inherited metabolic disorders: sickle-cell disease, congenital adrenal hyperplasia, galactosemia, biotinidase deficiency, maple syrup urine disease, homocystinuria, cystic fibrosis, Duchenne muscular dystrophy, glucose-6-phosphate dehydrogenase deficiency, pyroglutamic aciduria, and arginase deficiency. Having the opportunity to design our program from the start has permitted us to include screening for conditions with extensive worldwide experience and acceptance, as well as for lesser-known and less widely accepted conditions. It has also allowed us to develop and introduce some exciting new technologies as part of our routine confirmation procedures.
reaction (PCR) amplification of the DNA eluted from a single filter paper blood spot, we are able to screen for the presence of the common three base pair deletion (delta F508) associated with CF [6] . Among known patients with CF, 50 percent are homozygous for this deletion, while another 41-44 percent are mixed heterozygotes for the delta F508 deletion plus a second mutant allele. The remaining 6-9 percent have two copies of mutations other than the delta F508 deletion. This information is illustrated in Fig. 1 .
Since January 1990, we have been performing PCR amplification for the delta F508 deletion on every filter paper blood specimen in which we find an elevated IRT. We expect that this practice will improve both the sensitivity and specificity of our CF screening program in two ways. The ability to combine IRT elevations with delta F508 status should reduce the risk of a potential false-negative resulting from an inaccurate sweat test. We also hope to be able to redefine our IRT screening cut-off level and follow-up criteria, using a combination of IRT and delta F508 status, in the hope of reducing the number of false-positives that are referred for sweat testing.
A elevations, 12 persistent elevations on repeat testing, and ten confirmed cases of DMD, giving us an incidence of 1/7,300 newborns of both sexes.
Unlike the situation with CF, we are not primarily concerned about eliminating false-positives or false-negatives with DMD screening. Rather, we are trying to provide rapid confirmation of the diagnosis as early as possible, preferably before the patient is even referred to a DMD clinic for clinical evaluation and muscle biopsy. To do this, we are using multiplex PCR amplification of DNA from the initial filter paper blood specimens of newborns with two creatine kinase elevations [11, 12] . Due in part to very large size, the gene mutations responsible for DMD can be directly identified in 65 percent of patients as deletions of specific exons within the dystrophin gene [13] . Using multiplex PCR, we are able to identify 80 percent of these deletions and, therefore, confirm the diagnosis in approximately half of our patients before we even request a follow-up quantitative serum creatine kinase. We feel that this confirmation helps significantly in the early management of the patient and family. Figure 2 illustrates an example of a multiplex PCR amplification of a newborn DMD patient with a significant deletion.
As part of an expanded confirmation protocol, we routinely request quantitative serum creatine kinase analysis, clinical evaluation, family history, and routine histology of a muscle biopsy for confirmation of the diagnosis. We also carry out additional Southern blot analysis on the patient, using various probes to define further and characterize the mutation or deletion at the DNA level. This practice, together with the multiplex PCR studies, can provide the basis for carrier testing of at-risk family members and potentially has some prognostic value. Also, in collabora-tion with Dr. Eric Hoffman, we are determining the dystrophin status of the muscle, using both immunoblot and immunofluorescent assays on biopsies [14] [15] . This technique permits us to distinguish the more severe DMD from the milder Becker muscular dystrophy in an asymptomatic newborn with no positive family history. Without this expanded follow-up protocol, one might have to wait for years to determine the patient's prognosis.
In summary, what we have done is to adapt several molecular genetic techniques for use with DNA eluted from filter paper blood specimens and to incorporate these into the routine follow-up and confirmation protocols for our supplemental newborn screening program for DMD and CF. While we are not using multiplex PCR or delta F508 analysis for primary screening or carrier testing, we are using these techniques to improve the sensitivity and specificity of our existing creatine kinase and IRT screening for DMD and CF, respectively. As automated procedures are developed and as the cost decreases, however, we are optimistic that the use of these or similar molecular tests on filter paper blood specimens will become practical for primary screening in the not too distant future.
